Benzodiazepine dependence: Focus on withdrawal syndrome

Annales Pharmaceutiques Francaises

Volumn 67, Issue 6, 2009, Pages 408-413

  Authier, N ^a,b,d   Balayssac, D ^a,b   Sautereau, M ^c   Zangarelli, A ^a   Courty, P ^c   Somogyi, A A ^d   Vennat, B ^a   Llorca, P M ^c   Eschalier, A ^b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Addiction; Benzodiazepine; Dependence; Drug abuse; Elderly; Pregnancy

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; COCAINE; FLUMAZENIL; HYPNOTIC AGENT; MELATONIN; MIDAZOLAM; MOOD STABILIZER; OPIATE DERIVATIVE;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY DISORDER; CHILD CARE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTINUOUS INFUSION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG USE; DRUG WITHDRAWAL; ELDERLY CARE; FETOTOXICITY; GASTROINTESTINAL SYMPTOM; GROUP THERAPY; HIGH RISK PATIENT; HUMAN; INSOMNIA; LOW DRUG DOSE; MENTAL DISEASE; MOOD DISORDER; NEUROLOGIC DISEASE; NEUROMODULATION; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT EDUCATION; PHARMACEUTICAL CARE; PHYSICAL DISEASE; PREGNANT WOMAN; PRESCRIPTION; PSYCHOPATHY; RELAPSE; SCHIZOPHRENIA; SHORT SURVEY; SOCIOECONOMICS; TERATOGENICITY; TOXICOKINETICS; WITHDRAWAL SYNDROME;

ADULT; AGED; AGING; ALCOHOLISM; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PREGNANCY; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 70350726221     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2009.07.001     Document Type: Short Survey

References (30)

1. Australian Bureau of Statistics. National Health Survey, First Results, Australia, Canberra 1996. Report 4377.0. Available from: URL: http://www.abs.gov.au/ [consulted 01.04.2009].
2. Holden J.D., Hughes I.M., and Tree A. Benzodiazepine prescribing and withdrawal for 3234 patients in 15 general practices. Fam Pract 11 (1994) 358-362
3. The ESEMeD/MHEDEA 2000 investigators. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiological of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004;109:55-64.
4. Lagnaoui R., Depont F., Fourrier A., Abouelfath A., Bégaud B., Verdoux H., et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 60 (2004) 523-529
5. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 18 (2005) 249-255
6. Neutel C.I. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 17 (2005) 189-197
7. Morin C.M., Bastien C., Guay B., Radouco-Thomas M., Leblanc J., and Vallières A. Randomized clinical trials of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry 161 (2004) 332-342
8. Swortfiguer D., Cissoko H., Giraudeau B., Jonville-Béra A.P., Bensouda L., and Autret-Leca E. Neonatal consequences of benzodiazepines used during the last month of pregnancy. Arch Pediatr 12 (2005) 1327-1331
9. Wikner B.N., Stiller C., Bergman U., Asker C., and Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidem Druf Saf 16 (2007) 1203-1210
10. Birchley G. Opioid and benzodiazepine withdrawal syndromes in the paediatric intensive care unit: a review of recent literature. Nurs Crit Care 14 (2009) 26-37
11. Ista E., van Dijk M., Gamel C., Tibboel D., and de Hoog M. Withdrawal symptoms in children after long-term administration of sedatives and/or analgesics: a literature review. Int Care Med 33 (2007) 1396-1406
12. Lavie E., Fatséas M., Denis C., and Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend 99 (2009) 338-344
13. Lader M., Tylee A., and Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 23 (2009) 19-34
14. Veronese A., Garatti M., Cipriani A., and Barbui C. Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation. Eur J Clin Pharmacol 63 (2007) 867-873
15. Volz A., Khorsand V., Gillies D., and Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 1 (2007) 1-15
16. O'Brien C.P. Benzodiazepine use, abuse and dependence. J Clin Psychiatry 66 (2005) 28-33
17. Ashton H. Benzodiazepine abuse, drugs and dependence (2002), Harwood Academic Publishers, London & New York
18. Wafford K.A. GABAa receptor subtypes: any clues to the mechanism of benzodiazepine dependence?. Curr Opin Pharmacol 5 (2005) 47-52
19. Souza-Pinto L.F.S., Castilho V.M., Brandao M.L., and Nobre M.J. The blockade of AMPA-kainate and NMDA receptors in the dorsal periaqueductal gray reduces the effects of diazepam withdrawal in rats. Pharmacol Biochem Behav 87 (2007) 250-257
20. Das P., Lilly S.M., Zerda R., Gunning III W.T., Alvarez F.J., and Tietz E.I. Increased AMPA receptor GluR1 subunit incorporation in rat hippocampal CA1 synapses during benzodiazepine withdrawal. J Comp Neurol 511 (2008) 832-846
21. Xiang K., Earl D.E., Davis K.M., Giovannucci D.R., Greenfield Jr. L.J., and Tietz E.I. Chronic benzodiazepine administration potentiates high voltage-activated calcium currents in hippocampal CA1 neurons. J Pharmacol Exp Ther 327 (2008) 872-883
22. Skelton K.H., Nemeroff C.B., and Owens M.J. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression. J Neurosci 24 (2004) 9303-9312
23. Wichniak A., Brunner H., Ising M., Pedrosa Gil F., Holsboer F., and Friess E. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression. Psychoneuroendocrinology 29 (2004) 1101-1108
24. Heberlein A.M., Bleich S., Kornhuber J., and Hillemacher T. Neuroendocrine pathways in benzodiazepine dependence/new targets for research and therapy. Hum Psychopharmacol 23 (2008) 171-181
25. Skelton K.H., Gutman D.A., Thrivikraman K.V., Nemeroff C.B., and Owens M.J. The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. Psychopharmacology 192 (2007) 385-396
26. Khong E., Sim M.G., and Hulse G. Benzodiazepine dependence. Aus Fam Phys 33 (2004) 923-926
27. Denis C., Fatséas M., Lavie E., and Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 3 (2006) 1-19
28. Oude Voshaar R.C., Couvée J.E., Van Balkom A.J.L.M., Mulder P.G.H., and Zitman F.G. Strategies for discontinuing long-term benzodiazepine use. Br J Psychiatry 189 (2006) 213-220
29. Hood S., O'Neil G., and Hulse G. The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. J Psychopharmacol 23 (2009) 401-409
30. Parr J.M., Kavanagh D.J., Cahill L., Mitchell G., and Young R.M. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction 104 (2008) 13-24